Bone Biologics Co. (NASDAQ:BBLG) Short Interest Down 75.1% in March

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 31,100 shares, a decrease of 75.1% from the February 29th total of 124,800 shares. Based on an average daily trading volume, of 263,900 shares, the short-interest ratio is presently 0.1 days. Currently, 6.3% of the shares of the stock are short sold.

Bone Biologics Price Performance

Shares of NASDAQ:BBLG opened at $2.04 on Thursday. The company’s fifty day moving average price is $2.98 and its 200-day moving average price is $3.94. The firm has a market capitalization of $1.08 million, a price-to-earnings ratio of -0.04 and a beta of 0.18. Bone Biologics has a one year low of $2.03 and a one year high of $86.81.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1.